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Abstract
Hospitalized children < 2 years of age in Amman, Jordan, admitted for fever and/or respiratory symptoms, were tested for Middle East
respiratory syndrome coronavirus (MERS-CoV): MERS-CoV by real-time RT-PCR (rRT-PCR). This was a prospective year-round viral
surveillance study in children <2 years of age admitted with acute respiratory symptoms and/or fever from March 2010 to September
2012 and enrolled from a government-run hospital, Al-Bashir in Amman, Jordan. Clinical and demographic data, including antibiotic use,
were collected. Combined nasal/throat swabs were collected, aliquoted, and frozen at 80°C. Specimen aliquots were shipped to
Vanderbilt University and the Centers for Disease Control and Prevention (CDC), and tested by rRT-PCR for MERS-CoV. Of the
2433 subjects enrolled from 16 March 2010 to 10 September 2012, 2427 subjects had viral testing and clinical data. Of 1898
specimens prospectively tested for other viruses between 16 March 2010 and 18 March 2012, 474 samples did not have
other common respiratory viruses detected. These samples were tested at CDC for MERS-CoV and all were negative by rRT-PCR for
MERS-CoV. Of the remaining 531 samples, collected from 19 March 2012 to 10 September 2012 and tested at Vanderbilt,
none were positive for MERS-CoV. Our negative ﬁndings from a large sample of young Jordanian children hospitalized with fever
and/or respiratory symptoms suggest that MERS-CoV was not widely circulating in Amman, Jordan, during the 30-month period
of prospective, active surveillance occurring before and after the ﬁrst documented MERS-CoV outbreak in the Middle East
region.
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We tested upper respiratory tract specimens for MERS-CoV
in young children. Our study is the ﬁrst to describe a large
cohort of children with ARI symptoms during this same time
period and we did not detect MERS-CoV.
*This article was amended on 12/12/2013 after initial online
publication 09/12/2013. The author X. Lu was incorrectly cited
as L. Xiaoyan.
Introduction
The recent emergence of Middle East respiratory syndrome
coronavirus (MERS-CoV) [1,2], ﬁrst discovered in September
2012, has led to enhanced surveillance efforts throughout the
world to detect new cases in a timely manner and to better
understand the transmission and pathogenesis of the virus.
Coronaviruses are a diverse group of positive-strand RNA
viruses that commonly infect the respiratory and gastrointes-
tinal tracts of mammals and birds. Human coronaviruses are
most commonly associated with mild respiratory illnesses, but
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can cause severe illness, such as severe acute respiratory
syndrome (SARS) coronavirus. Genetic sequencing data indi-
cate that the MERS-CoV is a betacoronavirus closely related to
two bat coronaviruses (HKU4 and HKU5), but distinct from
other human coronaviruses, including SARS-CoV [1,3].
As of November 11, 2013, World Health Organization
(WHO) has been informed of a total of 151 laboratory-
conﬁrmed cases of infection with MERS-CoV, including 64
deaths [4]. The cases have originated from the following
countries Middle Eastern countries to date: Jordan, Qatar,
Saudi Arabia and the United Arab Emirates (UAE). France,
Germany, Spain, Italy, Tunisia and the United Kingdom have
also reported laboratory-conﬁrmed cases [2,4, 5]. The ﬁrst
known MERS-CoV infections were detected retrospectively
as occurring in April 2012 in Jordan [6]. Based on conﬁrmed
cases to date, the clinical syndrome consists of febrile illness
and pneumonia, as well as renal failure in some patients. The
majority of reported cases have been in adults and 64 of
151 cases have been fatal (42%) [4]. Some cases have
occurred in clusters. One cluster involved two cases, both
fatal, occurring near Amman, Jordan (Zarga, 20 km in
distance), in April 2012 [6]. Stored samples from these
two cases (one hospital worker and one student) tested
positive for MERS-CoV retrospectively, and this cluster was
temporally associated with cases of illness among hospital
workers. Several other clusters suggested human transmis-
sion [5,7,8]; although the risk of sustained transmission is
unknown [2,5].
The epidemiology of MERS-CoV, including its potential
distribution among paediatric cases of severe acute respira-
tory illness (ARI), has not been characterized. A critical
question is whether the cases identiﬁed thus far are the only
MERS-CoV infections or whether the virus has circulated
more widely undetected. This is of interest in light of the
epidemiology of SARS-CoV, where infections in children
< 12 years of age were generally milder, with no mortality
and few hospitalizations [9]. To determine whether MERS-
CoV was present among young paediatric ARI cases before,
during and after the occurrence of the Zarga, Jordan
MERS-CoV cluster, we tested upper respiratory tract spec-
imens collected from a prospective study of paediatric ARI
hospitalizations in Amman, Jordan, from March 2010 to
September 2012.
Methods
Study design
A prospective year-round viral surveillance study in children
<2 years admitted with respiratory symptoms and/or fever
commenced on 16 March 2010 at Al Basheer Hospital, the
main government-run hospital and referral centre in Amman,
Jordan, with 240 paediatric hospital beds and catchment of
approximately one million persons (50% of the population).
Subjects were enrolled 5 days per week (Sunday–Thursday)
for approximately 30 months from March 2010 to September
2012. After consent was obtained, the child’s clinical symptoms
before admission to the hospital and demographic information
were collected by parental interview. Medical records were
reviewed to determine the hospital course and clinical
outcomes. Institutional Review Board approval was obtained
from Vanderbilt University, Jordan University and the Jorda-
nian Ministry of Health.
Specimen collection
Nasal and throat swabs were collected and combined in
transport medium (M4RT, Remel, Lenexa, KS, USA), aliquot-
ed into MagMAXTM Lysis/Binding Solution Concentrate (Life
Technologies, Grand Island, NY, USA), snap frozen, and stored
at 80°C. Original and lysis buffer aliquots were shipped to
Vanderbilt University on dry ice for testing by real-time
RT-PCR (rRT-PCR) for respiratory syncytial virus, human
metapneumovirus, rhinovirus, inﬂuenza A and B, and parain-
ﬂuenza virus one, two and three [10]. Samples tested by
Vanderbilt that had no viruses detected were sent to the CDC
for MERS-CoV testing and samples not previously tested for
any respiratory viruses were tested for MERS-CoV at
Vanderbilt.
Laboratory methods
At Vanderbilt. PCR testing—Nucleic acid extraction and real-time
RT-PCR (rRT-PCR) testing. RNA was extracted from thawed
specimens according to the manufacturer’s protocols for the
MagMAX-96TM Viral RNA Isolation Kit (Life Technologies).
Primers and probes were synthesized by a commercial supplier
(Euroﬁns MWG Operon, Huntsville, AL, USA) based on
previously described sequences [11]. rRT-PCR assays were
designed to target the upE and ORF1b regions of the
MERS-CoV genome. As a positive control, the target sequence
of the upE assay and ﬂanking nucleotides (c. 400 bp total) were
synthesized by a commercial source (Genscript, Piscataway,
NJ, USA) and cloned into plasmid pUC57. One-step rRT-PCR
reactions were prepared using the AgPath-ID One-Step
RT-PCR kit (Life Technologies) according to the manufac-
turer’s instructions with 400 nM forward and reverse primers
and 200 nM probe. Cycling parameters were 50°C 9 30 min,
95°C 9 10 min and 45 cycles of 95°C 9 15 s and
58°C 9 30 s, with ﬂuorescence data collected during the
60°C annealing/extension step. Specimens were tested ﬁrst by
the upE assay using 5 lL of RNA. Potential positives were then
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retested using the ORF1b assay and the upE assay was
repeated, both with 10 lL of RNA.
Culture—Cells and viruses. Vero and LLC-MK2 cells were
maintained in OptiMEM (Life Technologies) media supple-
mented with 2% fetal calf serum, gentamicin, amphotericin B,
glutamine and tylosin. All virus work was performed in a
biosafety level (BSL) three laboratory following IBC-approved
BSL-3 procedures.
Virus recovery. Vero and LLC-MK2 cells were plated in
25-cm2 ﬂasks. The next day, media was removed and then 1 ml
was added back. Frozen specimen aliquots were thawed on ice
and 75–100 lL of specimen or PBS (mock) were added to the
ﬂasks. Flasks were maintained at 37°C, 5% CO2 for 30 min,
with rocking every 10 min, and then 2 mL of Opti-MEM was
added to each ﬂask and ﬂasks were returned to the incubator.
Flasks were examined for cytopathic effect (CPE) every 24–
48 h.
At CDC. PCR testing—Brieﬂy, total nucleic acids (TNAs) were
extracted from 200 lL of the swab specimens using the
NucliSENS easyMAG (bioMerieux, Durham, NC, USA). All
specimens were tested by three discrete rRT-PCR assays: the
upE assay as described above and two in-house developed
assays targeting the MERS-CoV nucleocapsid gene. All assays
were performed in 25 lL ﬁnal reaction volumes containing
5 lL of sample TNA extract using the Invitrogen SuperScript
III Platinum One-Step Quantitative RT-PCR System (Life
Technologies) on an Applied Biosystems 7500 Fast Dx
Real-Time PCR instrument (Life Technologies). Positive test
results were assigned to samples generating well-deﬁned
ﬂuorescent curves that crossed the threshold within 45 cycles
for any assay and were further investigated. Positive (MERS-
CoV RNA transcript template) and negative (nuclease-free
water) controls were included in all runs to monitor assay
performance. All samples were also tested by rRT-PCR for the
presence of the human ribonuclease P gene as a control for
specimen quality.
Results
Of the 2433 subjects enrolled from 16 March 2010 to 10
September 2012, 2427 specimens were available for PCR
testing for MERS-CoV and had clinical data available. The
median age was 3.5 months, 60% were male, and 10% had an
underlying medical condition, 30% required oxygen, 11% had
the diagnosis of pneumonia and 7% were admitted to the
ICU. In addition, 2% attended day care and 76% were
exposed to smokers. The majority (97%) of the fathers were
employed, and 39.6%, 44.8% and 10% of the mothers ﬁnished
primary education, secondary education and college, respec-
tively. The majority of children lived in Amman; however,
some children lived in the surrounding cities, including Zarqa
(34 children, 1.4%). Table 1 includes demographic data,
diagnoses and outcome data for the entire group and by
testing sites.
Of 1898 specimens prospectively tested for other viruses
during 2-year surveillance period between 16 March 2010
and 18 March 2012, 474 samples did not have other
common respiratory viruses detected. These samples were
tested at CDC for MERS-CoV and none were found to be
positive by rRT-PCR for MERS-CoV. The remaining 531
samples collected from 19 March 2012 to 10 September
2012 were tested at Vanderbilt using the MERS-CoV upE
assay with 5 lL of RNA extract per reaction. Four of the
samples gave positive reactions with high cycle threshold (Ct)
values (c. 38). These specimens were retested using the upE
TABLE 1. Patient characteristics of the Jordanian hospitalized children < 2 years of age with fever and/or respiratory symptoms
Tested for MERS at
CDC N = 474 (%)
Tested for MERS at
Vanderbilt N = 531 (%)
Not tested for MERS due to
other virus detected N = 1422 (%)
Combined population
N = 2427 (%) p-Value
Age (months) 2.8 3.2 3.8 3.5 <0.01
Sex (male) 297 (63) 339 (64) 830 (58) 1466 (60) 0.047
Prior medical history 54 (11) 70 (13) 114 (8) 238 (10) 0.001
Daycare 6 (1) 8 (2) 25 (2) 39 (2) 0.75
Exposure to smoke 371 (78) 403 (76) 1081 (76) 1855 (76) 0.57
Mother employed 26 (5) 30 (6) 96 (7) 152 (6) 0.5
Father employed 456 (96) 516 (97) 1375 (97) 2347 (97) 0.69
Number days sick prior
to admission (median)
2.0 3.0 3.0 3.0 <0.01
Length of stay (median) 4.2 4.2 4.2 4.2 0.80
Diagnosis
Pneumonia 30 (6) 71 (13) 168 (12) 269 (11) <0.01
Bronchiolitis 34 (7) 50 (9) 328 (23) 412 (17) <0.01
Bronchopneumonia 132 (28) 165 (31) 506 (36) 803 (33) 0.004
Sepsis ruled out 213 (45) 182 (34) 278 (20) 673 (28) <0.01
ICU admission 49 (10) 49 (9) 134 (9) 232 (10) 0.81
Oxygen use 92 (19) 155 (29) 487 (35) 734 (30) <0.01
Discharge status = death 7 (1) 5 (1) 10 (1) 22 (1) 0.31
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and Orf1b rRT-PCR assays with 10 lL of RNA per reaction
and all were negative. Finally, these specimens were retested
using the CDC MERS-CoV nucleocapsid primers and probes
provided to Vanderbilt and were also negative. These four
specimens were then inoculated into Vero and LLC-MK2
cells. Three of the samples showed evidence of bacterial or
fungal contamination within 24–48 h following inoculation
and were discarded and not recultured due to lack of an
adequate amount of samples. Cells inoculated with the fourth
sample were monitored for 7 days and then passaged into
new cultures and followed for an additional 10 days. No CPE
was detected.
Comparisons among the three groups were made using the
Kruskal–Wallis test or Pearson chi-square test for continuous
variables and categorical variables, respectively.
Discussion
Despite the close proximity of the ﬁrst documented
MERS-CoV outbreak in Zarga in April 2012, we did not
detect MERS-CoV among children < 2 years of age who
were hospitalized with ARI during that same time period in
Amman, Jordan, just 20 km away. Young children are known
to be a source of respiratory viral transmission; therefore,
our negative ﬁndings epidemiologically suggest that
MERS-CoV may not have been widely circulating in nearby
metropolitan Amman, Jordan, during this interval. This is an
important ﬁnding because there remains uncertainty over
whether conﬁrmed MERS-CoV cases are more likely to be
detected due to the severity of illness, and the full extent
to which MERS-CoV circulates more widely causing mild
illness [8]. Nevertheless, further surveillance is still needed
in the Arabian Peninsula and neighbouring countries to
monitor current circulation and possible emergence of
widespread transmission. The majority of the MERS-CoV
cases reported to date have been in adults and the common
symptoms have included fever, cough and shortness of
breath, with a high proportion of cases resulting in death
[1,2,5,6,8].
Four specimens tested preliminarily positive for MERS-CoV
by the upE rRT-PCR assay, albeit with high Ct values; however,
further testing conﬁrmed that these were false-positive results.
This illustrates that with any assay, even in an experienced
laboratory, false positives can occur. Thus, given the public
health importance of this virus, further conﬁrmatory testing
should be performed on all provisionally test-positive speci-
mens.
Our study is limited by the fact that only hospitalized
children with ARI were enrolled, and thus we may have missed
milder cases of MERS-CoV infection among outpatient
children. For example, children < 12 years of age infected
with SARS-CoV were reported to have milder disease
compared with older children and adults [9,12,13]. Nose/
throat swabs obtained during acute respiratory disease were
tested, and the sensitivity of this specimen type for detecting
MERS-CoV is currently unknown. The CDC recommends
collecting respiratory specimens from different sites and at
different stages of the illness, with lower respiratory tract
specimens prioritized, but existing routine surveillance in the
Middle East and elsewhere typically focuses on nose/throat
swabs [5,14]. Only samples that tested negative for a virus
were sent to the CDC for testing; therefore, we may have
missed instances of MERS-CoV co-infections, but all respira-
tory samples collected after the ﬁrst MERS-CoV cluster
occured in Jordan in April 2012 were tested. However, a
strength of our study is that we tested almost 1000 children
hospitalized with ARI symptoms for MERS-CoV. Of note,
another study described lack of detecting MERS-CoV from
nasal swabs from a group of French Hajj pilgrims after
returning to France, despite a high rate of respiratory
symptoms [15].
In conclusion, our negative ﬁndings suggest that MERS-CoV
has not widely circulated in Amman, Jordan, during the
30-month period of prospective, active surveillance occurring
before and after the ﬁrst documented outbreak of MERS-CoV
in the region. Our study conﬁrms the value of prospective viral
surveillance infrastructure to facilitate rapid responses to
emerging pathogens.
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